Herbalife Ltd. announced its financial results for the second quarter of 2026. Net sales were $1.3 billion, a 5.4% year-over-year increase, and the fourth consecutive quarter of year-over-year net sales growth for the company. Adjusted EBITDA was on the upper end of guidance at $166.6 million with a diluted loss per share of $0.25.
“Our net sales and EBITDA results for the second quarter were at the high end of previously issued guidance,” said John DeSimone, Herbalife Chief Financial Officer. “While the recent strengthening of the US dollar has resulted in additional foreign exchange headwinds affecting our reported outlook for the back half of the year, our constant currency outlook remains consistent with the expectations we shared last quarter.”
In North America, net sales were $273 million, a 0.2% improvement from the same quarter in 2025. Latin America and Asia Pacific grew 16.6% and 15.2% respectively, while EMEA declined 3.5% and China net sales fell 24.5% year-over-year.
Year-to-date, net sales were $2.6 billion worldwide with Asia Pacific showing 16.3% year-over-year growth and $966 million in net sales, and Latin America reporting 16.8% year-over-year growth and $487 million in net sales.
“We delivered a fourth consecutive quarter of year-over-year net sales growth, and we continue to expect net sales growth for the remainder of the year,” said Stephan Gratziani, Herbalife CEO. “This momentum reflects the resilience of Herbalife and has us poised to successfully carry out our long-term growth strategy.”
As a result of direct distributor feedback, the company rolled out the next release of its Pro2col platform and debuted a new user experience, enhanced features and integration with blood test diagnostics. At-home blood biomarker diagnostics was also unveiled and became available to select distributors in North America last month.
Full-year 2026 guidance now includes net sales of $5 billion with a narrowed adjusted EBITDA guidance range between $670 million to $690 million.
